Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964330 | 0.84 | ADRB2 (0.61) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL10720145 | 0.81 | ADRB2 (0.77) | ADRB2ADRB3KDM4EGAASMN1; SMN2 | |
| SCHEMBL5964589 | 0.81 | ADRB2 (0.68) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL5964373 | 0.81 | ADRB3 (0.59) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL9467104 | 0.81 | ADRB2 (0.68) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL5964674 | 0.79 | ADRB3 (0.56) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL9543386 | 0.79 | ADRB2 (0.73) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL4467889 | 0.79 | ADRB2 (0.73) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL4467885 | 0.79 | ADRB2 (0.73) | ADRB2ADRB3ADRB1KDM4EGAA | |
| SCHEMBL5963830 | 0.78 | ADRB2 (0.56) | ADRB2ADRB3ADRB1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052315-A1 | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | CNR1, CNR2, OPRL1 | ADRB2 15/4885ADRB3 86/4885ADRB1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.